Möchten Sie immer auf dem neuesten Stand bleiben?

SAN DIEGO, Sept. 07, 2024 (GLOBE NEWSWIRE) -- Embrace Change Acquisition Corp. (Nasdaq: EMCG, EMCGW, EMCGU, EMCGR) ("Embrace Change" or the "Company"), announced today that on September 5, 2024, it...

TORONTO, 06 sept. 2024 (GLOBE NEWSWIRE) -- Investissements Purpose Inc. (« Purpose ») a annoncé aujourd’hui des changements au niveau de risque de 16 fonds d’investissement publics qu’elle gère...

TORONTO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Purpose Investments Inc. (“Purpose”) today announced changes to the risk ratings for 16 public investment funds under its management (collectively, the...

DALLAS, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies...

WESTLAKE VILLAGE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

Airship AI Announces Closing of $8.0 Million Public Offering

WALTHAM, Mass. and DUBLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...

CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...

BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective...

CALGARY, Alberta, Sept. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...